BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lopes AP, Mineiro MA, Costa F, Gomes J, Santos C, Antunes C, Maia D, Melo R, Canotilho M, Magalhães E, Vicente I, Valente C, Gonçalves BG, Conde B, Guimarães C, Sousa C, Amado J, Brandão ME, Sucena M, Oliveira MJ, Seixas S, Teixeira V, Telo L. Portuguese consensus document for the management of alpha-1-antitrypsin deficiency. Pulmonology 2018;24 Suppl 1:1-21. [PMID: 30473034 DOI: 10.1016/j.pulmoe.2018.09.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Dias E, Farinha I, Costa F. Alpha-1-antitrypsin deficiency (AATD) and spontaneous pneumothorax: Guidelines do not recommend screening for AATD in patients with pneumothorax - What did we find in 10 years of clinical evidence? Pulmonology 2021;27:80-1. [PMID: 32553825 DOI: 10.1016/j.pulmoe.2020.05.014] [Reference Citation Analysis]
2 Sucena M, Gomes J, Guimarães C, Miravitlles M. Implementation of European Alpha-1 Research Collaboration (EARCO) in Portugal: the future starts now. Pulmonology 2020;26:181-3. [DOI: 10.1016/j.pulmoe.2020.01.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Sousa CS, Teixeira V, Pereira V, Pinheiro RB, Seixas S, Martins N. A rare case of pulmonary disease combining alpha-1-antitrypsin deficiency and common variable immunodeficiency. Pulmonology 2020;26:406-9. [PMID: 32518030 DOI: 10.1016/j.pulmoe.2020.04.016] [Reference Citation Analysis]
4 Seixas S, Marques PI. Known Mutations at the Cause of Alpha-1 Antitrypsin Deficiency an Updated Overview of SERPINA1 Variation Spectrum. Appl Clin Genet 2021;14:173-94. [PMID: 33790624 DOI: 10.2147/TACG.S257511] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Santos GF, Ellis P, Farrugia D, Turner AM. Nephrotic syndrome secondary to alpha-1 antitrypsin deficiency. BMJ Case Rep 2021;14:e240288. [PMID: 33674298 DOI: 10.1136/bcr-2020-240288] [Reference Citation Analysis]
6 Cardoso J, Ferreira AJ, Guimarães M, Oliveira AS, Simão P, Sucena M. Treatable Traits in COPD - A Proposed Approach. Int J Chron Obstruct Pulmon Dis 2021;16:3167-82. [PMID: 34824530 DOI: 10.2147/COPD.S330817] [Reference Citation Analysis]
7 Annunziata A, Ferrarotti I, Coppola A, Lanza M, Imitazione P, Spinelli S, Micco PD, Fiorentino G. Alpha-1 Antitrypsin Screening in a Selected Cohort of Patients Affected by Chronic Pulmonary Diseases in Naples, Italy. J Clin Med 2021;10:1546. [PMID: 33916947 DOI: 10.3390/jcm10081546] [Reference Citation Analysis]
8 Jardim JR, Casas-Maldonado F, Fernandes FLA, Castellano MVCO, Torres-Durán M, Miravitlles M. Update on and future perspectives for the diagnosis of alpha-1 antitrypsin deficiency in Brazil. J Bras Pneumol 2021;47:e20200380. [PMID: 34076174 DOI: 10.36416/1806-3756/e20200380] [Reference Citation Analysis]
9 Greulich T, Albert A, Cassel W, Boeselt T, Peychev E, Klemmer A, Ferreira F, Clarenbach C, Torres-Duran ML, Turner AM, Miravitlles M. Opinions and Attitudes of Pulmonologists About Augmentation Therapy in Patients with Alpha-1 Antitrypsin Deficiency. A Survey of the EARCO Group. Int J Chron Obstruct Pulmon Dis 2022;17:53-64. [PMID: 35023913 DOI: 10.2147/COPD.S346051] [Reference Citation Analysis]
10 Martín T, Miravitlles M, Furtado ST. A PI*MS is not always a PI*MS. An example of when genotyping for alpha-1 antitrypsin deficiency is necessary. Pulmonology 2021;27:272-3. [PMID: 32723617 DOI: 10.1016/j.pulmoe.2020.06.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 López-Campos JL, Carrasco Hernandez L, Caballero Eraso C. Implications of a Change of Paradigm in Alpha1 Antitrypsin Deficiency Augmentation Therapy: From Biochemical to Clinical Efficacy. J Clin Med 2020;9:E2526. [PMID: 32764414 DOI: 10.3390/jcm9082526] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Duarte-de-Araújo A, Teixeira P, Hespanhol V, Correia-de-Sousa J. COPD: How can evidence from randomised controlled trials apply to patients treated in everyday clinical practice? Pulmonology 2020:S2531-0437(20)30027-1. [PMID: 32169297 DOI: 10.1016/j.pulmoe.2020.02.003] [Reference Citation Analysis]
13 Afonso M, Silva C, Pinho I, Vale A, Fernandes A. A rare mutation on alpha-1 antitrypsin deficit and lung fibrosis: case report. Sarcoidosis Vasc Diffuse Lung Dis 2020;37:e2020019. [PMID: 33597804 DOI: 10.36141/svdld.v37i4.9877] [Reference Citation Analysis]
14 Santos G, Turner AM. Alpha-1 antitrypsin deficiency: an update on clinical aspects of diagnosis and management. Fac Rev 2020;9:1. [PMID: 33659933 DOI: 10.12703/b/9-1] [Reference Citation Analysis]
15 Hernández-Pérez JM, Ramos-Díaz R, Vaquerizo-Pollino C, Pérez JA. Frequency of alleles and genotypes associated with alpha-1 antitrypsin deficiency in clinical and general populations: Revelations about underdiagnosis. Pulmonology 2022:S2531-0437(22)00030-7. [PMID: 35346640 DOI: 10.1016/j.pulmoe.2022.01.017] [Reference Citation Analysis]